This content is machine translated Chronic inflammatory bowel disease Therapy in transition: innovation through biologics In treatment-resistant severe cases, a biologic representative of a new substance class, vedolizumab, is now available in addition to conventional standard medication and anti-TNFα. Several evaluations of different therapies from…
